InnoCare Pharma announced today that the first patient was dosed in the phase II registrational trial of tafasitamab in combination with lenalidomide for adult patients in China who have relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and are not eligible for autologous stem cell transplantation (ASCT).
Dr. Jasmine Cui, Co-founder, Chairwoman and CEO of InnoCare, said,
